Drug Trial Radar · NCT02452424
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Last checked: Nov 20, 2026Latest source record: Mar 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
78
Actual
Start
Jul 2, 2015
Primary completion
Aug 17, 2018
Study completion Oct 12, 2018
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- Plexxikon; Merck Sharp & Dohme LLC
- First posted
- May 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R). Pembrolizumab is designed to block the interaction between the receptor PD-1 and molecules that bind PD-1. In this study, PLX3397 and pembrolizumab are being given together in order to study their combined effects on patients' immune responses to their tumors. Tumor-specific immune responses have been shown to kill cancer cells and/or to stop tumors from growing. Part 1 of the study (dose-escalation phase) will establish the safest dose of PLX3397 to be given in combination with pembrolizumab. Part 2 of the study (expansion phase) will include an evaluation of efficacy of this combination in the following tumor types: * Advanced melanoma: prior anti-PD-1/PD-L1 therapy but never responded * Advanced melanoma: prior anti-PD-1/PD-L1 therapy and responded but later progressed as defined by irRECIST while on therapy * Non-small cell lung cancer * Ovarian cancer * Gastrointestinal Stromal Tumor (GIST) * Squamous cell cancer of the head and neck
Conditions
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Gastrointestinal Stromal Tumor (GIST)
- Ovarian Cancer
Interventions
PLX3397Drug
PLX3397 capsules, 200 mg
PembrolizumabBiological
Pembrolizumab, 200 mg, IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent Adverse Events (TEAEs) in Participants Regardless of Causality While Taking PLX3397 in Combination With PembrolizumabTime frame: 1 year (Dose Escalation); 2 years (Dose Expansion)
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Research Institute
Scottsdale, Arizona
Marin Cancer Care
Greenbrae, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Washington University St. Louis Siteman Cancer Center
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
Medical University Health Hollings Cancer Center
Charleston, South Carolina
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
South Texas Accelerated Research Therapeutics
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.